# APIM Therapeutics AS

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/apim-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Trondheim, Norway
- Website: www.apimtherapeutics.com
- Total disclosed funding: $0.5M
- Latest round: Seed (Nov 10, 2011)
- Investors on record: 3

## About

APIM Therapeutics AS is a biotechnology firm focused on developing peptide drugs that target PCNA-dependent stress responses in cancer cells, aiming to provide innovative therapeutic interventions for oncology.Founded in 2009 in Trondheim, Norway, APIM Therapeutics AS specializes in peptide drug development for cancer treatments. The company has engaged in five notable deals since its inception, with the latest funding round occurring in December 2017, where it raised NOK 25 million from investors including Bergens forskningsstiftelse and Investinor. The CEO, Kostas Alevizopoulos, leads the company as it focuses on the clinical development of its lead product, ATX-101, addressing cancer therapies.APIM Therapeutics AS specializes in developing peptide drugs that target PCNA-dependent stress responses in cancer cells, particularly through its lead product, ATX-101. This drug aims to tackle critical mechanisms in cellular stress regulation and tumor evasion from therapy, undergoing clinical trials for ovarian cancer and sarcoma. The company targets oncologists and healthcare providers, offering treatments for patients with significant unmet medical needs, specifically in markets like Europe and North America.APIM Therapeutics AS operates under a revenue model centered on partnerships and collaborations, typical in the biotech sector. Revenue is generated through licensing agreements, clinical trial partnerships, and potential product sales, with ATX-101 as a key offering. The company’s interactions with clients are characterized by direct engagement aimed at ensuring support and information accompany their therapies, with pricing structures varying based on the complexity of cancer treatment solutions.APIM Therapeutics AS plans to utilize the NOK 25 million raised in December 2017 to file a Clinical Trial Application (CTA) and initiate the clinical development program for its lead anti-cancer compound, ATX-101. The company aims to expand its market presence in Europe and North America, focusing on providing advanced therapeutic options. Through this funding, APIM Therapeutics seeks to bring ATX-101 to market, paving the way for innovative treatment solutions in oncology.

## Funding rounds

- Seed, Nov 10, 2011 — Sarsia, Birk Venture, Ro Invest AS
- Seed, Mar 21, 2011 — Sarsia
- Seed, May 27, 2010, $0.5M — Sarsia

## Investors

- Sarsia (https://capitalatlas.ai/funds/sarsia) — Seed
- Birk Venture — Seed
- Ro Invest AS — Seed